Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-2920
Abstract: Abstract Purpose: Signal transducer and activator of transcription 3 is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase I study of TTI-101, a first-in-class,… read more here.
Keywords: cancer; tti 101; first class; solid tumors ... See more keywords
A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.tps577
Abstract: TPS577 Background: STAT3 (signal transducer and activator of transcription 3) is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Persistent STAT3… read more here.
Keywords: cohort; tti 101; 101 monotherapy; study ... See more keywords